IARTQT48Integra LifeSciences Holdings Corporation·NASDAQ
13.61+6.75%
TA
Loading chart...
Screen all →
Snapshot
Index—P/E80.06EPS (ttm)0.17Insider Own17.34%Shs Outstand77.77MPerf Week12.48%
Market Cap1.06BForward P/E5.70EPS next Y2.39Insider Trans0.00%Shs Float58.64MPerf Month7.33%
Enterprise Value2.73BPEG9.34EPS next Q0.69Short Float12.48%Perf Quarter-23.97%
Income12.00MP/S0.64EPS this Y6.49%Short Ratio7.92Perf Half Y27.79%
Sales1.66BP/B0.99EPS next Y1.88%ROA0.37%Short Interest7.32MPerf YTD9.58%
Book/sh13.72P/C3.39EPS next 5Y8.57%ROE1.24%52W High20.49 -33.58%Perf Year15.24%
Cash/sh4.01P/FCF10.69EPS past 3/5Y—ROIC11.42%52W Low8.70 56.44%Perf 3Y-61.69%
Dividend Est.—EV/EBITDA11.68Sales past 3/5Y1.62% 3.57%Gross Margin52.46%Volatility5.12% 5.29%Perf 5Y-80.71%
Dividend TTM—EV/Sales1.65EPS Y/Y TTM—Oper. Margin38.30%ATR (14)0.75Perf 10Y-66.59%
Dividend Ex-Date—Quick Ratio2.21Sales Y/Y TTM0.79%Profit Margin0.79%RSI (14)50.86Recom2.71
Dividend Gr. 3/5Y—Current Ratio3.62EPS Q/Q9.26%SMA204.97%Beta1.26Target Price15.80
Payout0.00%Debt/Eq1.86Sales Q/Q2.24%SMA50-7.87%Rel Volume1.57Prev Close12.75
Employees4,427LT Debt/Eq1.82EarningsFeb 25SMA200-3.27%Avg Volume957.46KPrice13.61
IPO DateAug 16, 1995Option/ShortYes / YesEPS/Sales Surpr.5.85% -0.48%Net Debt/EBITDA7.16Volume1,504,288Change6.75%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-27-26ReiteratedUBSNeutral$19 → $14
Oct-22-26ReiteratedWells FargoEqual Weight$15 → $13
Oct-22-26ReiteratedBMO CapitalMarket Perform$19 → $14
Oct-03-26ReiteratedWells FargoEqual Weight$18 → $15
Jul-28-26InitiatedUBSNeutral$19
Jul-16-26ReiteratedTruist SecuritiesHold$12 → $19
Jul-08-26ReiteratedBMO Capital$19
Jun-18-26ReiteratedArgus ResearchHold$25
May-28-26UpgradeCitigroupSell → Neutral
Apr-15-26DowngradeArgus ResearchBuy → Hold
Latest News· Times ET
Oct-30-26
Oct-27-26
Oct-23-26
Oct-22-26
Oct-21-26
Company

Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,6571,6351,6111,542—————
Cost of Goods Sold Incl. D&A788790728657—————
Gross Profit869845882885—————
Selling, General and Administrative Excl. Other684700717657—————
Research and Development9599115104—————
Other Operating Expense-545-222212—————
Operating Income6346828112—————
Interest Expense97867151—————
Unusual Expense
—————————
Non-Operating Income (Expense)-516-5462421—————
Net Income Before Taxes23-564-1881—————
Income Taxes9-47-1113—————
Consolidated Net Income12-516-768—————
Net Income From Continuing Operations12-516-768—————
Net Income12-516-768—————
EPS (Recurring)0.17-6.73-0.090.87—————
EPS (Basic, Before Extraordinaries)0.17-6.73-0.090.87—————
EPS (Diluted)0.17-6.73-0.090.84—————
EBITDA234-325193256—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio80.06——51.85—————
Price To Sales Ratio0.650.581.082.20—————
Gross Margin52.4451.6854.7557.39—————
Operating Margin38.264.161.747.26—————
Net Margin0.72-31.56-0.434.41—————
Shares Outstanding79777778—————
Market Capitalization1,0759561,7463,397—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$21.49$17.93$14.38$10.82$7.26● Close Price0.00K25.54K51.08K76.61K102.15KUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Singh HarvinderEVP & PRESIDENT, INTERNATIONALMar 11 '26Option Exercise0.0037,844040,612Mar 12
Singh HarvinderEVP & PRESIDENT, INTERNATIONALMar 10 '26Option Exercise0.001,216023,152Mar 12
Poul MojdehPresident & CEOJan 06 '26Option Exercise0.001,39001,390Jan 07
GRAVES JEFFREY ADirectorNov 05 '25Buy11.359,000102,15041,086Nov 06
Singh HarvinderEVP & PRESIDENT, INTERNATIONALOct 12 '25Option Exercise0.0011,965025,217Oct 14
Singh HarvinderEVP & PRESIDENT, INTERNATIONALMar 11 '25Option Exercise0.002,35604,391Mar 13
Singh HarvinderEVP & PRESIDENT, INTERNATIONALMar 10 '25Option Exercise0.001,18002,359Mar 11
Schwartz EricEVP, Chief Legal Officer & SecDec 03 '24Sale24.594,070100,10259,511Dec 04
McBreen Michael J.EVP & President, CSSDec 02 '24Sale24.161,70041,06456,182Dec 03
De Witte JanPresident & CEONov 01 '24Option Exercise0.009,814028,164Nov 04
Mosebrook JeffreySVP, Fin & Princ Acct OfficerAug 19 '24Sale21.581,19125,70136,088Aug 20
ESSIG STUARTExec. Chairman of the BoardMay 23 '24Buy28.4952,6411,499,979487,922May 24
HILL BARBARA BDirectorMay 21 '24Buy27.4036,350995,81636,350May 22
De Witte JanPresident & CEOMar 11 '24Option Exercise0.00205018,555Mar 13
De Witte JanPresident & CEOMar 10 '24Option Exercise0.00346018,696Mar 12
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.